Articoli con mandati relativi all'accesso pubblico - Elisa RumiUlteriori informazioni
Non disponibili pubblicamente: 13
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
T Barbui, AM Vannucchi, V De Stefano, A Masciulli, A Carobbio, A Ferrari, ...
The Lancet Haematology 8 (3), e175-e184, 2021
Mandati: Fondazione AIRC per la Ricerca sul Cancro
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene
E Rumi, JD Milosevic, D Selleslag, I Casetti, E Lierman, D Pietra, ...
Annals of hematology 94, 1927-1928, 2015
Mandati: Governo Italiano
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients
F Passamonti, B Mora, T Giorgino, P Guglielmelli, M Cazzola, M Maffioli, ...
Leukemia 31 (4), 970-973, 2017
Mandati: Fondazione Cariplo, Governo Italiano
LNK mutations in familial myeloproliferative neoplasms
E Rumi, AS Harutyunyan, D Pietra, JDM Feenstra, C Cavalloni, ...
Blood, The Journal of the American Society of Hematology 128 (1), 144-145, 2016
Mandati: Austrian Science Fund, German Research Foundation
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms
G Todisco, M Creignou, A Gallì, P Guglielmelli, E Rumi, M Roncador, ...
Leukemia 35 (8), 2371-2381, 2021
Mandati: Swedish Research Council, Governo Italiano, Fondazione AIRC per la Ricerca …
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
A Alvarez-Larrán, E Sant'Antonio, C Harrison, JJ Kiladjian, ...
The Lancet Haematology 8 (9), e658-e665, 2021
Mandati: Cancer Research UK, Wellcome Trust
Diagnosis and management of prefibrotic myelofibrosis
E Rumi, E Sant’Antonio, E Boveri, D Pietra, C Cavalloni, E Roncoroni, ...
Expert review of hematology 11 (7), 537-545, 2018
Mandati: Governo Italiano
Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation
G Rotunno, C Mannarelli, G Brogi, A Pacilli, F Gesullo, F Mannelli, ...
Blood, The Journal of the American Society of Hematology 133 (26), 2802-2808, 2019
Mandati: Governo Italiano
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis
B Mora, C Siracusa, E Rumi, M Maffioli, IC Casetti, D Barraco, M Merli, ...
Leukemia 35 (5), 1490-1493, 2021
Mandati: Governo Italiano
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis.
C Trotti, E Sant'Antonio, D Vanni, IC Casetti, O Borsani, D Pietra, ...
Hematological Oncology 39 (4), 2021
Mandati: Governo Italiano, Fondazione AIRC per la Ricerca sul Cancro
Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib
E Rumi, E Sant'Antonio, C Cavalloni, G Comolli, VV Ferretti, I Cassaniti, ...
Hematological Oncology 38 (4), 554-559, 2020
Mandati: Governo Italiano, Fondazione AIRC per la Ricerca sul Cancro
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms
G Rotunno, P Guglielmelli, F Biamonte, E Rumi, M Cazzola, ...
Annals of hematology 93, 523-524, 2014
Mandati: Governo Italiano
Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)
C Paoli, P Guglielmelli, F Mannelli, M Borella, V Rosti, E Rumi, ...
Blood 140 (Supplement 1), 6840-6841, 2022
Mandati: Fondazione AIRC per la Ricerca sul Cancro
Disponibili pubblicamente: 76
Mutations and prognosis in primary myelofibrosis
AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ...
Leukemia 27 (9), 1861-1869, 2013
Mandati: Governo Italiano
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
E Rumi, D Pietra, V Ferretti, T Klampfl, AS Harutyunyan, JD Milosevic, ...
Blood, The Journal of the American Society of Hematology 123 (10), 1544-1551, 2014
Mandati: Austrian Science Fund, Governo Italiano
MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis
P Guglielmelli, TL Lasho, G Rotunno, M Mudireddy, C Mannarelli, ...
Journal of Clinical Oncology 36 (4), 310-318, 2018
Mandati: Governo Italiano
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
E Rumi, D Pietra, C Pascutto, P Guglielmelli, A Martínez-Trillos, I Casetti, ...
Blood, The Journal of the American Society of Hematology 124 (7), 1062-1069, 2014
Mandati: Government of Spain, Governo Italiano
Clinical significance of somatic mutation in unexplained blood cytopenia
L Malcovati, A Gallì, E Travaglino, I Ambaglio, E Rizzo, E Molteni, C Elena, ...
Blood, The Journal of the American Society of Hematology 129 (25), 3371-3378, 2017
Mandati: Cancer Research UK
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
D Pietra, S Li, A Brisci, F Passamonti, E Rumi, A Theocharides, M Ferrari, ...
Blood, The Journal of the American Society of Hematology 111 (3), 1686-1689, 2008
Mandati: Swiss National Science Foundation
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
P Guglielmelli, TL Lasho, G Rotunno, J Score, C Mannarelli, A Pancrazzi, ...
Leukemia 28 (9), 1804-1810, 2014
Mandati: Governo Italiano
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software